scholarly journals Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma

2019 ◽  
Vol 6 ◽  
pp. 237428951984835 ◽  
Author(s):  
MacLean P. Nasrallah ◽  
Zev A. Binder ◽  
Derek A. Oldridge ◽  
Jianhua Zhao ◽  
David B. Lieberman ◽  
...  

Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline for efficient and optimal workup of glioblastomas based on our routine performance of molecular testing. We describe our institution’s testing algorithm, assay development, and genetic findings in glioblastoma, to illustrate current practices and challenges in neuropathology related to molecular and genetic testing. We have found that coordination of test requisition, tissue handling, and incorporation of results into the final pathologic diagnosis by the neuropathologist improve patient care. Here, we present analysis of O6-methylguanine-DNA-methyltransferase promoter methylation and next-generation sequencing results of 189 patients, obtained utilizing our internal processes led by the neuropathology team. Our institutional pathway for neuropathologist-driven molecular testing has streamlined the management of glioblastoma samples for efficient return of results for incorporation of genomic data into the pathological diagnosis and optimal patient care.

2016 ◽  
Vol 16 (6) ◽  
pp. 455-464 ◽  
Author(s):  
Kalkunte S. Srivenugopal ◽  
Amit Rawat ◽  
Suryakant K. Niture ◽  
Ameya Paranjpe ◽  
Chinavenmani Velu ◽  
...  

2016 ◽  
Vol 13 (1) ◽  
pp. 28-39 ◽  
Author(s):  
Patrick-Denis St-Coeur ◽  
Marc Cormier ◽  
Veronique LeBlanc ◽  
Pier Morin ◽  
Mohamed Touaibia

1990 ◽  
Vol 265 (25) ◽  
pp. 14754-14762
Author(s):  
G. Koike ◽  
H. Maki ◽  
H. Takeya ◽  
H. Hayakawa ◽  
M. Sekiguchi

2021 ◽  
Vol 22 (13) ◽  
pp. 7039
Author(s):  
Wojciech Jelski ◽  
Barbara Mroczko

Brain tumors are the most common malignant primary intracranial tumors of the central nervous system. They are often recognized too late for successful therapy. Minimally invasive methods are needed to establish a diagnosis or monitor the response to treatment of CNS tumors. Brain tumors release molecular information into the circulation. Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a substitute for tumor tissue. Tumor-derived biomarkers include nucleic acids, proteins, and tumor-derived extracellular vesicles that accumulate in blood or cerebrospinal fluid. In recent years, circulating tumor cells have also been identified in the blood of glioblastoma patients. In this review of the literature, the authors highlight the significance, regulation, and prevalence of molecular biomarkers such as O6-methylguanine-DNA methyltransferase, epidermal growth factor receptor, and isocitrate dehydrogenase. Herein, we critically review the available literature on plasma circulating tumor cells (CTCs), cell-free tumors (ctDNAs), circulating cell-free microRNAs (cfmiRNAs), and circulating extracellular vesicles (EVs) for the diagnosis and monitoring of brain tumor. Currently available markers have significant limitations.While much research has been conductedon these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature.


Sign in / Sign up

Export Citation Format

Share Document